 |
|
 |
BIBLIOGRAPHY
 ADJUVANT TREATMENT WITH ZOLEDRONIC ACID IN STAGE II/II BREAST CANCER. THE AZURE TRIAL (BIG 01/04).
Coleman RE, Thorpe HC, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Davies C, Bell R. Weston Park Hospital, Sheffield, United Kingdom, University of Leeds, United Kingdom, AZURE (BIG 01/01) Investigators.
SABCS 2010
|
CETUXIMAB + CISPLATIN IN ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-NEGATIVE, HER2-NEGATIVE (TRIPLE-NEGATIVE) METASTATIC BREAST CANCER: RESULTS OF THE RANDOMIZED PHASE II BALI-1 TRIAL.
Baselga J, Stemmer S, Pego A, Chan A, Goeminne J-C, Graas M-P, Kennedy J, Ciruelos Gil EM, Zubel A, Groos J, Kia U, Schneeweiss A.
SABCS 2010
|
OVERALL SURVIVAL DATA FROM SOLTI-0701: A MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2B STUDY EVALUATING THE ORAL COMBINATION OF SORAFENIB AND CAPECITABINE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER.
Gómez P, Roché H, Costa F, Segalla JGM, Pinczowski H, Ciruelos EM, Cabral Filho S, Van Eyll B, Baselga J.
Poster SABCS 2010
|
FIRST RESULTS OF THE NEOALTTO TRIAL (BIG 01-06/EGF 106903): A PHASE III , RANDOMIZED, OPEN LABEL, NEOADJUVANT STUDY OF LAPATINIB, TRASTUZUMAB, AND THEIR COMBINATION PLUS PACLITAXEL IN WOMEN WITH HER 2-POSITIVE PRIMARY BREAST CANCER.
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E, Gomez H, Dinh P, Fauria K, Van Dooren V, Paoletti P, Goldhirsch A, Chang T-W, Lang I, Untch M, Gelber RD, Piccart-Gebhart M, On behalf of the NeoALTO Study Team.
SABCS 2010
|
ADJUVANT CHEMOTHERAPY PRESCRIPTION ACCORDING TO MULTIDISCIPLINARY TEAM DECISION OR THE MINDACT PROTOCOL (MICROARRAY IN NODE-NEGATIVE AND 1 TO 3 POSITIVE LYMPH NODE DISEASE MAY AVOID CHEMOTHERAPY) (EORTC10041 BIG 3-04)
Carine Mitine, Haine Saint Paul, Belgium.
ESMO Milan 08-12 October 2010 Poster 243P
|
SORAFENIB PLUS CAPECITABINE IN PATIENTS WITH TRIPLE-NEGATIVE ADVANCED BREAST CANCER: SUBGROUP ANALYSIS OF SOLTI-0701, A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED PHASE 2B STUDY.
H. Roché, J.G.M. Segalla, A. del Giglio, E.M. Ciruelos, S. Cabral Filho, P. Gomez, A. Lluch, A. Llombart, F. Costa, J. Baselga.
ESMO Milan 08-12 October 2010 Poster 300P
|
THE ADDITION OF CETUXIMAB TO CISPLATIN INCREASES OVERALL RESPONSE RATE (ORR) AND PROGRESSION-FREE SURVIVAL (PFS) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC): RESULTS OF A RANDOMIZED PHASE II STUDY (BALI-1).
Baselga J, Gomez P, Awada A, Greil R, Braga S, Climent MA, Wardley A, Zubel A, Groos J, Kaufman B.
ESMO Milan 08-12 October 2010. Oral presentation Abstract 2740
|
EUROPEAN COOPERATIVE TRIALS IN OPERABLE BREAST CANCER II (ECTO II): LOCO-REGIONAL EFFECTS OF PRIMARY CHEMOTHERAPY IN TWO PARALLEL RANDOMIZED PHASE II TRIALS IN ER-POSITIVE AND ER-NEGATIVE EARLY BREAST CANCER.
Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, Ciruelos E, Pavesi L, Semiglazov V, Gianni L. Fondazione Michelangelo, Milano, Italy.
Breast Cancer Symposium, Washington 1-3 October 2010. Abts 117
|
LONGER-TERM ASSESSMENT OF TRASTUZUMAB-RELATED CARDIAC ADVERSE EVENTS IN THE HERCEPTIN ADJUVANT (HERA)TRIAL.
Marion Procter, Thomas M. Suter, Evandro de Azambuja, Urania Dafni, Veerle Van Dooren, Susanne Muehlbauer, Miguel Angel Climent, Raimund Jakesz , Walter Tsang-Wu Liu , Mazakasu Toi, Charles Coombes, David Dodwell, Olivia Pagani, Jorge Madrid, Marcia Hall, Shin-Cheh Chen, Christian Focan, Michael Muschol, Dirk van Veldhuisen, Martine J. Piccart-Gebhart for the HERA trial study team.
JCO 2010 Jul 20;28(21):3422-8. Epub 2010 Jun 7
|
THE EFFECTS OF ADDING ZOLEDRONIC ACID TO NEOADJUVANT CHEMOTHERAPY ON TUMOUR RESPONSE: EXPLORATORY EVIDENCE FOR DIRECT ANTI-TUMOUR ACTIVITY IN BREAST CANCER.
RE Coleman, MC Winter, D Cameron, R Bell, D Dodwell, MM Keane, M Gil, D Ritchie, JL Passos-Coelho, D Wheatley, R Burkinshaw, SJ Marshall and H Thorpe on behalf of the AZURE (BIG01/04) Investigators.
British Journal of Cancer (2010) 102, 1099–1105. doi:10.1038/sj.bjc.6605604
|
SOLTI-0701: A DOUBLE-BLIND, RANDOMISED PHASE 2B STUDY EVALUATING SORAFENIB (SOR) IN COMBINATION WITH CAPECITABINE (CAP) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (BC).
Baselga J, SOLTI Breast Cancer Group, Roche H, Costa F, Segalla JGM, Pinczowski H, Ciruelos E, Filho SC, Gomez P, Van Eyll B.
IMPAKT 2010. Annals of Oncology 21(Supplement 4), May 2010: 60-64. Abts 138P
|
MULTIVARIATE ANALYSIS (MVA) OF PROGRESSION-FREE SURVIVAL (PFS) IN TWO PHASE IIB, MULTINATIONAL, DOUBLE-BLIND, RANDOMIZED, PLACEBO (PL)-CONTROLLED TRIALS EVALUATING SORAFENIB (SOR) PLUS STANDARD CHEMOTHERAPY IN PATIENTS (PTS) WITH HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (BC).
Gradishar WJ, Dalenc F, Kaklamani VG, Costa F, Sahoo TP, Segalla J, Lokanatha D, Pinczowski H, Raina V, Baselga J.
ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol Vol 28, No. 15S (May 20 Supplement), 2010: 1073
|
MANAGEMENT OF HAND-FOOT SKIN REACTION (HFSR)/HAND-FOOT SYNDROME (HFS) IN SOLTI-0701: A DOUBLE-BLIND, RANDOMIZED PHASE IIB STUDY COMPARING SORAFENIB (SOR) VERSUS PLACEBO (PL) IN COMBINATION WITH CAPECITABINE (CAP) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (BC).
P. Gomez, H. H. Roche, F. Costa, J. Segalla, H. Pinczowski, S. Cabral Filho, E. Ciruelos, B. M. Van Eyll and J. Baselga
Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 28, No 15_suppl (May 20 Supplement), 2010: 1083
|
NEOADJUVANT CHEMOTHERAPY WITH TRASTUZUMAB FOLLOWED BY ADJUVANT TRASTUZUMAB VERSUS NEOADJUVANT CHEMOTHERAPY ALONE, IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED BREAST CANCER (THE NOAH TRIAL): A RANDOMISED CONTROLLED SUPERIORITY TRIAL WITH A PARALLEL HER2-NEGATIVE COHORT.
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J.
Lancet 2010 Jan 30;375(9712):377-84
|
NEOADJUVANT TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED BREAST CANCER: PRIMARY EFFICACY
ANALYSIS OF THE NOAH TRIAL.
Gianni L, Eiermann W, Semiglazov V, Manikhas GM, Lluch A, Tjulandin S, Feyereislova A, Valagussa P, Baselga J. Istituto
Nazionale Tumori Milano, Italy; Frauenklinik Vom Roten Kreuz, Munich, Germany; NN Petrov Research Institute of
Oncology, St Petersburg, Russian Federation; City Oncology Hospital, St Petersburg, Russian Federation; Hospital Clínico
Universitario de Valencia, Spain; NN Blokhin Russian Cancer Research Centre, Moscow, Russian Federation; F Hoffmann-
La Roche, Basel, Switzerland; Fondazione Michelangelo, Milan, Italy; Vall d’Hebron University Hospital, Barcelona, Spain.
Proceedings SABCS, Cancer Res 2009
|
PHASE II RANDOMIZED STUDY OF NEOADYUVANT EVEROLIMUS PLUS LETROZOLE COMPARED WITH PALCEBO PLUS LETROZOLE IN PATIENTYS WITH ESTROGEN RECEPTOR-POSITIVE BREAST CANCER.
Baselga, J. Semiglazov, P. Van Dam, A. Manikhas, M. Bellet, J Mayordomo, M Compone, E Kubista, R Greil, G Bianci, J Steinseifer, B Molloy, E Tokaji, H Gardner, P Phillips, M Stumm, HA Lane, J M Dixon, W Jonat, H S Rugo.
J Clin Oncol. 2009; 27:2630-2637.
|
SOLTI-0701: A MULTINATIONAL DOUBLE-BLIND, RANDOMIZED PHASE 2B STUDY EVALUATING THE EFFICACY AND SAFETY OF SORAFENIB COMPARED TO PLACEBO WHEN ADMINISTERED IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER.
Baselga J, Grupo Español de estudio tratamiento y otras estrategias experimentales en tumores sólidos, Roché H, Costa F, Getúlio Martins Segalla J, Pinczowski H, Ma Ciruelos E, Cabral Filho S, Gómez P, Van Eyll B.
San Antonio Breast Cancer Symoposium, December 11, 2009. Cancer Res 2009;69(24 Suppl):Abstract nr 45.
|
GEMCITABINE AND CAPECITABINE IN PREVIOUSLY ANTHRACYCLINE-TREATED METASTATIC BREAST CANCER: A MULTICENTER PHASE II STUDY (SOLTI 0301 TRIAL).
Ciruelos EM, Cortés J, Cortés-Funes H, Mayordomo JI, Bermejo B, Ojeda B, García E, Rodríguez CA, Muñoz M, Gómez P, Manso L, Andrés R, Lluch A, Saura C, Mendiola C, Baselga J.
Ann Oncol. 2009 Nov 25.
|
EUROPEAN COOPERATIVE TRIAL IN OPERABLE BREAST CANCER II (ECTO II): ACTIVITY OF PRIMARY CHEMOTHERAPY IN ER NEGATIVE EARLY BREAST CANCER.
M. Zambetti, G. Pascoletti, P. Gomez, V. Semiglazov, A. Lluch, E. De Benedictis,B. Ojeda, C. Dittrich, P. Valagussa, L. Gianni
ECCO 15-34th ESMO. Berlin 20-24 Sept 2009. Abst. 5142. Eur J Cancer Supplements, Vol. 7, Issue 2, Sep 2009, Page 302
|
SOLTI-0701: A DOUBLE-BLIND, RANDOMIZED PHASE 2B STUDY EVALUATING THE EFFICACY AND SAFETY OF SORAFENIB (SOR) COMPARED TO PLACEBO (PL) WHEN ADMINISTERED IN COMBINATION WITH CAPECITABINE (CAP) IN PATIENTS (PTS) WITH LOCALLY ADVANCED (ADV)
J. Baselga ; J.G.M. Segalla; H. Roché; A. del Giglio; E.M. Ciruelos; S. Cabral Filho; P. Gomez; A. Lluch; A. Llombart; F. Costa
European Journal of Cancer Supplements, Vol. 7, No 3, September 2009, Page 3
|
PHASE IIB DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIALS FOR THE, EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS (PTS) WITH METASTATIC OR LOCALLY ADVANCED BREAST CANCER (BC): REVIEW OF THE TRIALS TO INVESTIGATE THE EFFECTS OF SORAFENIB IN BC (TIES) PROGRAM.
Baselga J, Gianni L, Gradishar WJ, Hudis C, Perez EA, Piccart-Gebhart M, Schwartzberg LS, Sledge G, Fleming TR.
ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: e12000
|
UTILITY OF SERUM HER2 EXTRACELLULAR DOMAIN ASSESSMENT IN CLINICAL DECISION MAKING: POOLED ANALYSIS OF FOUR TRIALS OF TRASTUZUMAB IN METASTATIC BREAST CANCER.
Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, Leyland-Jones B.
J Clin Oncol. 2009 Apr 1;27(10):1685-93.
|
UPDATE OF THE HERA TRIAL AND THE ROLE OF 1 YEAR TRASTUZUMAB AS ADJUVANT THERAPY FOR BREAST CANCER.
Gianni L, Goldhirsch A, Gelber RD, Azambuja E, Procter M, Untch M, Smith I, Jackisch C, Cameron D, Muehlbauer S, Leyland-Jones B, Piccart-Gebhart M, Baselga J, Bell R, for the HERA study team.
The Breast, volume 8, Supplement 1, March 2009, page S11, abstract S25
|
NONPEGYLATED LIPOSOMAL DOXORUBICIN (TLC-D99), PACLITAXEL, AND TRASTUZUMAB IN HER-2-OVEREXPRESSING BREAST CANCER: A MULTICENTER PHASE I/II STUDY
Javier Cortes1, Serena Di Cosimo1, Miguel A. Climent6, Hernán Cortés-Funes8, Ana Lluch7, Pere Gascón2, José I. Mayordomo11, Miguel Gil3, Manuel Benavides12, Lluís Cirera13, Belén Ojeda4, César A. Rodríguez14, José M. Trigo1, Josep Vazquez5, Pilar Regueiro9, Juan F. Dorado10, and José Baselga1 on behalf of the Spanish Breast Cancer Cooperative Group SOLTI
Authors´ Affiliations: 1 Vall d´Hebron University Hospital; 2 Hospital Clínic i Provincial de Barcelona; 3 Institut Català d´ Oncologia, Hospitalet de Llobregat; 4 Hospital Santa Creu i Sant Pau; 5 Spanish Breast Cancer Cooperative Group Operations Office, SOLTI, Barcelona, Spain; 6 Instituto Valenciano de Oncología; 7 Hospital Clínico Universitario, Valencia, Spain; 8 Hospital Universitario 12 de Octubre; 9 Roche Farma, S.A.; 10 SGS Life science Services, Madrid, Spain; 11 Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain; 12 Hospital Carlos Haya, Málaga, Spain; 13 Hospital Mútua de Terrasa, Terrasa, Spain; and 14 Hospital Clínico de Salamanca, Salamanca, Spain
Clinical Cancer Research 15, 307, January 1, 2009
|
ESTIMATING THE MAGNITUDE OF TRASTUZUMAB EFFECTS WITHIN PATIENT SUBGROUPS IN THE HERA TRIAL.
Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; HERA Study Team.
Ann Oncol. 2008 Jun;19(6):1090-6
|
FIRST REPORT OF THE EUROPEAN COOPERATIVE TRAIL IN OPERABLE BREAST CANCER II (ECTO II): EFFECTS OF PRIMARY CHEMO-ENDOCRINE THERAPY ON LOCAL-REGIONAL DISEASE IN ER-POSITIVE BREAST CANCER.
Zambetti M., Mansutti M., Llunch A., Zamagni C., De Benedictis E., Gomez L., Pavesi L., Dittrich C., Valagussa P., Gianni L.
Proceedings ASCO 26:28s, 2008 (abstract 588)
|
SURGICAL ASPECT IN NOAH PHASE III TRIAL (NEOADJUVANT TRASTUZUMAB IN HER2-POSITIVE LOCALLY ADVANCED BREAST CANCER).
V. Semiglazov, W. Eiermann, A. Manikhas, A. Bozok, A. Lluch, S. Tjulandin, A. Feyereislova, P. Valagussa, J. Baselga, L. Gianni.
EBCC 2008 Abstract 400. European Journal of Cancer Supplements Volume 6, No. 7, April 2008, page 169
|
EFFICACY OF NEOADJUVANT TRASTUZUMAB IN PATIENTS WITH INFLAMMATORY BREAST CANCER: DATA FROM NOAH (NEOANJUVANT HERCEPTIN) PHASE III TRIAL..
J. Baselga, et al.
ECCO 14, 2007
|
KEEPING FAITH WITH TRIAL VOLUNTEERS..
Piccart M, Goldhirsch A, Wood W, Pritchard K, Baselga J, Reaby L, Kossler I, Kyriakides S, Norton L, Coates A.
Nature. 2007; 446: 137-8
|
2-YEAR FOLLOW-UP OF TRASTUZUMAB AFTER ADJUVANT CHEMOTHERAPY IN HER2-POSITIVE BREAST CANCER: A RANDOMISED CONTROLLED TRIAL..
Smith I, Procter M, Gelber RD, et al. On behalf HERA study team
Lancet. 2007; 369:29-36
|
MULTICENTRIC PHASE II TRIAL OF GEMCITABINE PLUS CAPECITABINE COMBINATION IN THE TREATMENT OF PREVIOUSLY ANTHRACYCLINE(AN)-TREATED METASTATIC BREAST CANCER (MBC): SOLTI 0301 STUDY..
EM. Ciruelos, J Baselga, H Cortés-Funes, A Lluch, JI Mayordomo, B Ojeda, E. González, M. Muñoz, C Rodríguez, J Cortés. SOLTI Group, Spain. Abstract - No.
1051 ASCO Annual Meeting, 2007
|
BIOMARKER ANALYSIS OF A PHASE II DOUBLE-BLIND RANDOMIZED TRIAL OF DAILY ORAL RAD001 (EVEROLIMUS) PLUS LETROZOLE OR PLACEBO PLUS LETROZOLE AS NEOADJUVANT THERAPY FOR PATIENTS WITH ESTROGEN RECEPTOR POSITIVE BREAST CANCER.
Gardner H, Bandaru R, Barrett C, Calcaterra M, Crowell T, Decker J, Dixon M, Fisch R, Fuchs M, Gelb A, Hanoteau N, Jonat W, Lane H, Lebwohl D, Liu W-H, Molloy B, Pena C, Phillips P, Rheinhardt J, Rugo H, Salesky S, Steinseifer J, Stumm M, Tokaji E, Voelker F, Yarbrough G, Yateman N, Yu Y, Zuber E, Baselga J.. Novartis Institutes for Biomedical Research, Cambridge, MA; Novartis Pharmaceuticals, East Hanover, NJ; Hospital Vall d´Hebron, Barcelona, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Univ-Frauenklinik, Kiel, Germany; UCSF, San Francisco; Western General Hospital, Edinburgh, United Kingdom.
POSTER 4006 SABCS 2007
|
PHASE II DOUBLE-BLIND RANDOMIZED TRIAL OF DAILY ORAL RAD001 (EVEROLIMUS) PLUS LETROZOLE (LET) OR PLACEBO (P) PLUS LET AS NEOADJUVANT THERAPY FOR ER+ BREAST CANCER.
Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Dixon JM, Jonat W, Rugo HS.. Hospital Vall d´Hebron, Barcelona, Spain; NN Petrov Research Inst of Oncology, St. Petersburg, Russian Federation; Onc Centrum St Augustinus, Wilrijk, Belgium; City Oncological Dispensary, St. Petersburg, Russian Federation; Hospital Clinico Univ Lozana Blesa, Zaragoza, Spain; Centre Rene Gauducheau, Nantes, France; General Hospital, Vienna, Austria; Univ Hospital, Salzburg, Austria; Novartis Pharma AG, Basel, Switzerland; Istituto Nazionale Tumori, Milan, Italy; Western General Hospital, Edinburgh, United Kingdom; Univ-Frauenklinik, Kiel, Germany; Univ of CA SF, San Francisco, CA.
POSTER 2066 SABCS 2007
|
ESTUDIO MULTICÉNTRICO FASE II DE LA COMBINACIÓN DE GEMCITABINA Y CAPECITABINA EN EL TRATAMIENTO DEL CARCINOMA DE MAMA MESTASTÁSICO PREVIAMENTE TRATADO CON ANTRACICLINAS.
EM Ciruelos, Grupo SOLTI.
Presentación oral. Congreso Nacional SEOM Octubre 2007
|
NEOADJUVANT TRASTUZUMAB IN LOCALLY ADVANCED BREAST CANCER (NOAH):ANTITUMOR AND
SAFETY ANALYSIS .
L. Gianni,, et al.
Abs 532 ASCO Annual Meeting, 2007-08-07.
|
EVALUATION OF THE FEASIBILITY, SAFETY AND ANTITUMOURS EFFECTS OF NEOADJUVANT TRASTUZUMAB IN LOCALLY ADVANCED BREAST CANCER (NOAH TRIAL).
J. Baselga, et al.
ASCO Breast Symposium, 2007
|
A PHASE I TRIAL OF WEEKLY COMBINATION KOS-862 (EPOTHILONE D) AND TRASTUZUMAB IN HER-2 OVEREXPRESSING MALIGNANCIES..
Cortés, J, Climent M, Gómez P, Ruiz A, Calvo E, Zhang X, Pérez ES, DeMario M, Baselga J.
Abs 2028 ASCO Annual Meeting, 2006.
|
TRASTUZUMAB AFTER ADJUVANT CHEMOTHERAPY IN HER2-POSITIVE BREAST CANCER.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team.
N Engl J Med. 2005 Oct 20;353(16):1659-72.
|
UPDATED RESULTS OF A PHASE II STUDY (M77035) OF MYOCET® COMBINED WITH WEEKLY HERCEPTIN® AND PACLITAXEL IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (LABC/MBC)..
Cortés J,1 Climent MA,2 Lluch A,3 Hornedo J,4 Gascón P,5 Mayordomo J,6 Gil M,7 Benavides M,8 Regueiro P,9 Trigo J,1 Baselga J.1 on behalf of the Solti Group..
Abs 3041 27th Annual San Antonio Breast Cancer Symposium, 2004
|
RESULTS OF A PHASE II STUDY OF LIPOSOMAL DOXORUBICIN (MYOCET®) IN COMBINATION WITH WEEKLY PACLITAXEL AND TRASTUZUMAB (HERCEPTIN®) IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (LA/MBC).
J Baselga, MA Climent, A Lluch, J Hornedo, P Gascón, H Cortés-Funes, AT Sánchez, V Guillem, P Regueiro, J Trigo, on behalf of the SOLTI group.
Abs. 262 4th EBCC 2004. EJC 2004; 2: 132.
|
CARDIAC SAFETY AND EFFICACY FROM A PHASE I/II TRIAL OF THE LIPOSOMAL DOXORUBICIN MYOCET® IN COMBINATION WITH TRASTUZUMAB (HERCEPTIN®) AND PACLITAXEL IN PATIENTS WITH HHER2-POSITIVE (HER2+) LOCALLY ADVANCED OR METASTATIC BREAST CANCER (LA/MBC).
JM Trigo, MA Climent, M Gil, A Lluch, J Hornedo, P Gascón, V Guillem, P Regueiro, J Baselga.
EBCC, 2003 Poster.
|
LIPOSOMAL DOXORUBICIN (MYOCET®) IN COMBINATION WITH HERCEPTIN® AND PACLITAXEL, IS ACTIVE AND WELL TOLERATED IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (LA/MBC): A PHASE II STUDY.
Trigo JM, Climent MA, Lluch A, Gascón P, Hornedo J, Gil M, Cirera L, Guillem V, Regueiro P, Baselga J.
Abst. 351 Breast Cancer Res Treat 2003; S82, S83.
|
MOBILIZATION OF PERIPHERAL BLOOD PROGENITOR CELLS WITH A COMBINATION OF CYCLOPHOSPHAMIDE, R-METHUSCF AND FILGRASTIM IN PATIENTS WITH BREAST CANCER PREVIOUSLY TREATED WITH CHEMOTHERAPY.
Prosper, F.; Solà, C.; Hornedo, J.; Arbona, C.; Menéndez, P.; Orfao, A.; Lluch, A.; Cortés-Funes, H.; López, J.J.; García-Conde, J.
Leukemia 2003; 17: 437-441.
|
CARDIAC SAFETY AND ACTIVITY OF A PHASE I STUDY OF 3-WEEKLY MYOCET® IN COMBINATION WITH WEEKLY HERCEPTIN® AND PACLITAXEL IN HER2-POSITIVE (HER2+) LOCALLY ADVANCED OR METASTATIC BREAST CANCER (LA/MBC).
JM Trigo, MA Climent, M Gil, A Lluch, J Hornedo, P Gascón, V Guillem, P Regueiro, J Baselga on behalf of SOLTI Group.
Abst. 242 ASCO Annual Meeting 2002.
|
THE ROLE OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) IN THE POST-TRANSPLANT PERIOD.
Hornedo, J.; Solà, C.; Solano, C.; López, J.J.; Alonso, S.; Lluch, A.; Ojeda, Bl; García- Conde, J.; Cortés-Funes, H.
Bone Marrow Transplantation 2002; 29: 737-743.
|
PROGNOSTIC FACTORS FOR RELAPSED ALTER HIGH DOSE CHEMOTHERAPY (HDC) AND STEM CELL TRANSPLANT (SCT) IN PATIENTS WITH HIGH RISK BREAST CANCER (HRBC).
Prosper, F.; Solà, C.; Hornedo, J.; Climent, M.A.; Montes, A.; Benavides, M.; Baselga, J.; Mayordomo, J.I.; Alvarez, I.; López, J.J.; Cortés-Funes, H.; García-Conde, J.
Abs.581 American Society of Clinical Oncology (ASCO). 36th Annual Meeting. New Orleans, May 20-23,2000
|
HIGH-DOSE CHEMOTHERAPY (CT) WIHT PERIPHERAL STEM-CELL (PSCS) SEEMS TO IMPROVE DISEASE-FREE SURVIVAL (DFS) IN INFLAMMATORY BREAST CANCER (IBC) COMPARED WITH AN HISTORICAL SERIES OF PATIENTS (PTS).
Climent, M.A.; Solà, C.; Lluch, A.; Ruix, A.; Hornedo, J.; Benavides, M.; Montes, A.; Baselga, J.; López-López, J.; García-Conde,J.
Abs.548 American Society of Clinical Oncology (ASCO). 36th Annual Meeting. New Orleans, May 20-23, 2000
|
PHASE II STUDY OF WEEKLY PACLITAXEL (P) TREATMENT IN RECURRENT BREAST CANCER AFTER HIGH-DOSE CHEMOTHERAPY (HDC).
Sola C, Lluch A, García-Conde J, Salñazar R, García T, Montesinos J, Vera R, Benavides M, Climent MA, Hornedo J, Alvarez I, Prósper F, Cortés-Funes H, López-López JJ. SOLTI group Spain.
Proceedings ASCO 1999; 18:65a.
|
HIGH DOSE CHEMOTHERAPY (HDC) AND STEM CELL TRANSPLANT (SCT) FOR HIGH RISK BREAST CANCER (HRBC): RESULTS OF 235 TRANSPLANTS.
Lluch, A.; Solà, C.; Hornedo, J.; Germà, J.R.; Benavides, M.; Baselga, J.; Guillén, V.; Cruz, J.J.; Alvarez, I.; Mayordomo, J.I.; Prosper, F.; Ojeda, B.; Alonso, S.; Cortés-Funes, H.; López, J.J.; García-Conde, J.
Abstr 303 J. Clin. Oncol. American Society of Clinical Oncology (Asco). 35th Annual Meeting. Atlanta, 15-18 Mayo 1999.
|
PHASE II STUDY OF WEEKLY PACLITAXEL (P) TREATMENT IN RECURRENT BREAST CANCER ALTER HIGH-DOSE CHEMOTHERAPY (HDC) .
Solà, D.; Lluch, A.; García-Conde, J.; Salazar, R.; García, T.; Montesinos, J.; Vera, R.; Benavides, M.; Climent, M.A.; Hornedo, J.; Alvarez, I.; Prosper, F.; Cortés-Funes, H.; López-López, J.J.; Solti Group.
Abstr. 245 J. Clin. Oncol. American Society of Clinical Oncology (Asco). 35th Annual Meeting. Atlanta, 15-18 Mayo 1999
|
OUTCOME OF EXTENSIVE EVALUATION EEFOTE HIGH-DOSE CHEMOTHERAPY (HDC) IN PATIENTS (PTS) WITH HIGH-RISK.
López-López, J.J.; Lluch, A.; Solà, C.; Hornedo, J.; Climent, M.A.; Montes, A.;, Benavides, M.; Vera, R.; Cruz Hernández, J.; Alvarez, I.; Montesinos, J.; Salazar, R.; Prosper, F.; Alonso, S.; García-Conde.
J Breast Cancer (BC). Abstr.223: J. Clin. Oncol. American Society of Clinical Oncology (Asco). 35th Annual Meeting. Atlanta, 15-18 Mayo 1999.
|
PHASE II STUDY OF WEEKLY PACLITAXEL (P) IN RECURRENT BREAST CANCER ALTER HIGH-DOSE CHEMOTHERAPY (HDC).
Solà, D.; Lluch, A.; García-Conde, J.; Solano, C.; García, T.; et. al.
Thirty-Fourth Annual Meeting American Society of Clinical Oncology. Los Angeles, 16-19 Mayo 1998.
|
THE ROLE OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) IN THE POST-TRANSPLANT PERIOD. RESULTS OF A MULITCENTER, RANDOMIZED TRIAL IN BREAST CANCER (BC) PATIENTS (PTS) TREATED WITH HIGH-DOSE CHEMOTHERAPY AND C-CSF MOBILIZED, PERIPHERAL BLOOD STEM CELLS AUTOLOGOUS TRANSPLANTATION (PBSCT): EVIDENCE OF A SHORTENING IN THE HOSPITALIZATION TIME.
Hornedo, J.; Solà, C.; Solano, C.; Lluch, A.; García-Conde, J.; et. al.
Thirty-Fourth Annual Meeting American Society of Clinical Oncology. Los Angeles, 16-19 Mayo 1998.
|
MULTICENTER, PROSPECTIVE, RANDOMIZED STUDY OF THE ROLE OF GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) IN THE PROSTRANSPLANT PERIOD FOLLOWING HIGH-DOSE CHEMOTHERAPY 8HDC), SUPPORTED WITH G-CSF-MOBILIZED, PERIPHERAL BLOOD ÍTEM CELLS PBSC), IN BREAST CANCER PATIENTS (PTS).
Hornedo, J.; Solà, C.; Solano, C.; Lluch, A.; Benavides, M.; López, J.J.; García-Conde, J.; Cortés-Funes, H.
21st Congress European Society for Medical Oncology. Viena (Austria), 1-5, Noviembre 1996.
|
HIGH DOSE CHEMOTHERAPY (HDCT) AND AUTOLOGOUS PERIPHERAL ÍTEM-CELL TRANSPLANTATION 8APSCT) ALTER NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED (LABC) AND INFLAMMATORY BREAST CANCER.
García-Conde, J.; Cortés-Funes, H.; Hornedo, Lluch, A.;J.; C.; López-López, J.J.; Azagra, P.; Solano, C.; Solà, C..
21st Congress European Society for Medical Oncology. Viena (Austria), 1-5, Noviembre 1996.
|
HIGH DOSE CHEMOTHERAPY (HDCT) AND AUTOLOGOUS PERIPHERAL SÍTEM-CELL TRANSPLANTATION (APSCT) AFTER STANDARD CHEMOTHERAPY (CT) IN HIGH-RISK BREAST CANCER PATIENTS (GREATER THAN OR EQUAL TO 10 AXILLIARY NODE INVOLVEMENT AFTER SURGERY).
García-Conde, J.; Cortés-Funes, H.; Hornedo, Lluch, A.; López-López, J.J.; Azagra, P.; Solano, C.; Solà, C.
Thirty-Two Annual Meeting American Society of Clinical Oncology, 1996.
|
HIGH DOSE CHEMOTHERAPY (HDCT) AND AUTOLOGOUS PERIPHERAL SÍTEM-CELL TRANSPLANTATION (APSCT) AFTER STANDARD CHEMOTHERAPY (CT) IN HIGH-RISK BREAST CANCER PATIENTS (≥ 10 AXILLIARY NODE INVOLVEMENT AFTER SURGERY).
García-Conde J, Sola C, Solano C, Azaga P, Hornedo J, Cortés-Funes H, López JJ, Lluch A.
Thirty-Two Annual Meeting American Society of Clinical Oncology, 1996.
|
MULTICENTER STUDY ON THE EFFICACY OF FILGRASTIM IN OBTAINING CD34+ CELLS IN BREAST CANCER PATIENTS (PTS) PREVIOUSLY TREATED WITH CHEMOTHERAPY.
Hornedo, J.; Solà, C.; Solano, C.; López, JJ.; Lluch, A.;, García-Conde, J.; Cortés-Funes, H.
37th Annual Meeting of the ASH. Seattel, 1-5, Diciembre 1995.
|
ESTUDIO MULTICÉNTRICO SOBRE LA EFICACIA MOVILIZADOTA DEL FILGRASTIM (G-CSF) EN LA OBTENCIÓN DE CÉLULAS CD34+ EN PACIENTES (PTS) CON CÁNCER DE MAMA PREVIAMENTE TRATADAS CON QUIMIOTERAPIA.
Hornedo, J.; Solà, C.; Solano, C.; López, JJ.; Lluch, A.;, García-Conde, J.; Cortés-Funes, H.
XXXVII Reunión Nacional de la Asociación Española de Hematología y Hemoterapia. Zaragoza, 2-4 de Noviembre de 1995.
|
COMMENTED BIBLIOGRAPHY
PRESENTATIONS
|
|
|
|
 |
Who we are · Clinical Trials · Patients · Congresses · SOLTI Informs · Publications · Research guidelines